---
title: "DexCom, Inc. (DXCM.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/DXCM.US/overview.md"
symbol: "DXCM.US"
name: "DexCom, Inc."
parent: "https://longbridge.com/zh-CN/quote/DXCM.US.md"
datetime: "2026-04-05T03:16:53.897Z"
locales:
  - [en](https://longbridge.com/en/quote/DXCM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DXCM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DXCM.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/DXCM.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/DXCM.US/overview.md)


# DexCom, Inc. (DXCM.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Health Care Equipment |
| 交易所 | US Market |
| 地址 | 6340 Sequence Drive, San Diego, California, United States |
| 官网 | [www.dexcom.com](https://www.dexcom.com) |

## 公司简介

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Kevin Ronald Sayer | Executive Chairman of the Board |
| Jacob Steven Leach | President, CEO & Director |
| Jereme M. Sylvain | Executive VP, CFO & Chief Accounting Officer |
| Michael Jon Brown | Executive VP & Chief Legal Officer |
| Sadie M. Stern | Executive VP & Chief Human Resources Officer |
| Nicholas Augustinos | Independent Director |
| Mark G. Foletta | Lead Independent Director |
| Bridgette P. Heller | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| The Vanguard Group, Inc. | 12.75% | 2025-12-31 |
| BlackRock, Inc. | 10.35% | 2025-12-31 |
| State Street Global Advisors, Inc. | 4.70% | 2025-12-31 |
| Baillie Gifford & Co. | 4.04% | 2025-12-31 |
| Geode Capital Management, LLC | 2.86% | 2025-12-31 |
| UBS Asset Management AG | 2.58% | 2025-12-31 |
| AllianceBernstein L.P. | 2.24% | 2025-12-31 |
| Norges Bank Investment Management | 1.89% | 2025-12-31 |
| Jennison Associates LLC | 1.50% | 2025-12-31 |
| JP Morgan Asset Management | 1.31% | 2025-12-31 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| Patient Monitoring Equipment | 4662000000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "DexCom, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Patient Monitoring Equipment",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| United States (U.S.) | 3334900000 | 71.53% |
| International | 1327100000 | 28.47% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**